Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ImmuPharma drug needs further analysis; it could still have a role in treating lupus – City analyst

“We need to see more data,” said Northland Capital's Vadim Alexandre. “There is a major unmet medical"
test tubes
The reaction to the clinical trial was described as knee-jerk

ImmuPharma PLC's (LON:IMM) drug Lupuzor needs further analysis and certainly isn’t a bust, according to Vadim Alexandre, analyst at Northland Capital.

With shares down sharply on Tuesday, the reaction to phase III trial results for the lupus drug has been “knee-jerk” and probably not fully reflective of the outlook for the treatment, he said in an interview with Proactive’s Andrew Scott.

The readout from the study showed Lupuzor didn’t have a statistically significant impact on patients compared with the placebo plus the standard of care.

WATCH: Immupharma PLC still confident on Lupuzor's future

However, there are two points to grasp, Alexandre said. First, patients responded particularly well to the placebo plus standard of care because the cortical steroids worked. Second, the drug actually worked well in certain patient groups.

READ: Today's news

“We need to see more data,” Alexandre said. “There is a major unmet medical need and there has only been one drug out in the market in the last 50 years and that itself is not a perfect drug.”

On the news ImmuPharma is talking to potential partners, the Northland analyst added: “The primary end-point has not been met, but I think they will be looking at what the possibilities are for doing further and future trials.”

 

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use